NCT00337077: Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
|
|
| Completed | 2 | 121 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer | 06/09 | 11/13 | | |